Like The Herald Business Journal on Facebook!
The Herald of Everett, Washington
Heraldnet.com

The top local business stories in your email

Contact Us:

Josh O'Connor
Publisher
Phone: 425-339-3007
joconnor@heraldnet.com

Jody Knoblich
General Sales Manager
Phone: 425-339-3445
Fax: 425-339-3049
jknoblich@heraldnet.com

Jim Davis
Editor
Phone: 425-339-3097
jdavis@heraldnet.com

Site address:
1800 41st Street, S-300,
Everett, WA 98203

Mailing address:
P.O. Box 930
Everett, WA 98206

HBJ RSS feeds

Pfizer: 5 more countries OK arthritis pill Xeljanz

SHARE: facebook Twitter icon Linkedin icon Google+ icon Email icon |  PRINTER-FRIENDLY  |  COMMENTS
Associated Press
Published:
NEW YORK -- Several more countries have approved Pfizer Inc.'s new rheumatoid arthritis medicine, a twice-a-day pill viewed as a likely big seller.
The world's second-largest drugmaker says its Xeljanz has been approved in Russia, Argentina, Kuwait, the United Arab Emirates and Switzerland, the first European country to allow sales.
Meanwhile, New York-based Pfizer is asking advisers to European Union medical regulators to reconsider their recommendation not to approve the drug.
The advisers said Xeljanz didn't control progression of the immune disorder enough to outweigh serious side effects seen in some patients. Those include blood and other cancers, perforated intestines, tuberculosis and other infections, decreased infection-fighting cells, headaches and diarrhea.
Xeljanz, the first in a new class of drugs, was launched in the U.S. in November. It has been heavily advertised.

MORE HBJ HEADLINES

CALENDAR

Share your comments: Log in using your HeraldNet account or your Facebook, Twitter or Disqus profile. Comments that violate the rules are subject to removal. Please see our terms of use. Please note that you must verify your email address for your comments to appear.

You are logged in using your HeraldNet ID. Click here to update your profile. | Log out.

Our new comment system is not supported in IE 7. Please upgrade your browser here.

comments powered by Disqus

Market roundup